methylphenidate

(redirected from Quillivant XR)
Also found in: Dictionary, Thesaurus.

methylphenidate

 [meth″il-fenĭ-dāt]
a mild central nervous system stimulant; the hydrochloride salt is administered orally in the treatment of attention-deficit/hyperactivity disorder and narcolepsy.

methylphenidate

/meth·yl·phen·i·date/ (meth″il-fen´ĭ-dāt) a central stimulant, used in the form of the hydrochloride salt in the treatment of attention-deficit in children and narcolepsy.

methylphenidate

(mĕth′əl-fĕn′ĭ-dāt′, -fē′nĭ-)
n.
A drug, C14H19NO2, chemically related to amphetamine, that acts as a mild stimulant of the central nervous system and is used in its hydrochloride form to treat attention deficit hyperactivity disorder and narcolepsy.

methylphenidate

An amphetamine-derived CNS stimulant.
 
Adverse effects
Decreased appetite—10–15% of children have major weight loss; insomnia—most suffer sleep delay; abdominal pain; headaches; dry mouth; dizziness; depression, tachycardia; a proposed link to decreased growth is uncertain.
 
Indications for
Hyperactivity, ADD, childhood narcolepsy.

methylphenidate

Ritalin® Neuropharmacology An amphetamine derived CNS stimulant used to control ADD and hyperactivity in children Adverse effects ↓ Appetite, 10-15% of children have major weight loss; insomnia–most suffer sleep delay, abdominal pain, headaches, dry mouth, dizziness, depression, tachycardia; link with ↓ growth is uncertain Used for Hyperactivity; narcolepsy; ADD. See Amphetamine.

methylphenidate

A nervous system stimulant drug that, paradoxically, has been found effective in the management of ATTENTION-DEFICIT HYPERACTIVITY DISORDER in children. A brand name is Ritalin. The current consensus of opinion on the use of this drug for this purpose is that it is grossly over-prescribed, especially in the USA.

methylphenidate

a central nervous system stimulant used in the treatment of hyperkinesis and narcolepsy in dogs.
References in periodicals archive ?
By combining the advantages of Quillivant XR with Pfizer's commercialization expertise, we will be able to provide ADHD patients and their caregivers a new treatment option.
Healthcare company Pfizer Inc (NYSE:PFE) announced on Monday the availability in the US of Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension for the treatment of attention deficit hyperactivity disorder (ADHD).
Quillivant XR is reportedly the first once-daily, extended-release liquid methylphenidate for ADHD and is now available on prescription.
Pfizer said that Quillivant XR was approved by the US Food and Drug Administration (FDA) on 27 September 2012 for the treatment of ADHD in patients aged six years and above.
Following closing, Pfizer acquired the exclusive North American commercialisation rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the US for the treatment of ADHD.